Journal article
Clinical and Molecular Studies of the Effect of Imatinib on Advanced Aggressive Fibromatosis (desmoid tumor)
Abstract
PURPOSE: To determine the clinical efficacy of imatinib in patients with advanced aggressive fibromatosis (AF) and to identify the molecular basis of response/nonresponse to this agent.
PATIENTS AND METHODS: Nineteen patients with AF were treated with imatinib (800 mg/d) as part of a phase II clinical study. Tumor specimens were analyzed for mutations of KIT, PDGFRA, PDGFRB, and CTNNB1 (beta-catenin). Tumor expression of total and activated …
Authors
Heinrich MC; McArthur GA; Demetri GD; Joensuu H; Bono P; Herrmann R; Hirte H; Cresta S; Koslin DB; Corless CL
Journal
Journal of Clinical Oncology, Vol. 24, No. 7, pp. 1195–1203
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
March 1, 2006
DOI
10.1200/jco.2005.04.0717
ISSN
0732-183X
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdolescentAdultAntineoplastic AgentsBecaplerminBenzamidesClinical Trials, Phase II as TopicDisease-Free SurvivalFemaleDesmoid TumorsGene Expression Regulation, NeoplasticHumansImatinib MesylateImmunoblottingImmunohistochemistryMaleMiddle AgedMutationPiperazinesPlatelet-Derived Growth FactorPositron-Emission TomographyProtein Kinase InhibitorsProtein-Tyrosine KinasesProto-Oncogene Proteins c-kitProto-Oncogene Proteins c-sisPyrimidinesReceptor, Platelet-Derived Growth Factor alphaReceptor, Platelet-Derived Growth Factor betaTomography, X-Ray Computedbeta Catenin